Received Jul 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (NOVAVAX)) | NOVAVAX | 1 | EN5318 | SYR / LA |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | EN6198 | SYR / LA |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | FC3181 | SYR / LA |
Following sequential COVID-19 infections and COVID-19 vaccination, I experienced progressive, severe systemic microvascular and inflammatory symptoms. My infection history includes documented COVID-19 cases on 12/02/2021, 11/13/2022, 12/21/2023, and 01/24/2024. Each infection presented with worsening severity, including fevers reaching 105°F unresponsive to Tylenol and Motrin, severe headache, and profound fatigue. Subsequent to these events, I developed a severe 6-week non-COVID upper respiratory infection that failed to resolve until treated with high-dose oral steroids. Following steroid cessation, my symptoms progressed into chronic, multi-systemic microvascular dysfunction. Key Clinical Features & Symptoms: Systemic Capillary Leak & Fluid Shifts: Recurrent, cyclic weight fluctuations of 12 to 14 lbs within 48?72 hour windows (e.g., 147 lbs down to 142.9 lbs). Fluid shifts are accompanied by acute intravascular volume depletion, severe pre-syncope/dizziness, unsteadiness, headache, and nausea. Post-Exertional Anaerobic Stress: Marked post-exertional malaise and exercise intolerance following minor daily exertion. Pulmonary & Vascular Symptoms: Air hunger, breathing changes, and exertion-triggered vascular exhaustion - used to be a collegiate runner that was still active/competitive now can no longer run.
Covid 12-2-2021
none known before this except monitoring a bicuspid aortic valve
Cholestoff Complete, occasional zyrtec use
Statins, cat
Endothelial, Inflammatory & Immune Markers:Angiotensin-Converting Enzyme (ACE) Trend (Serially Escalating):April 2025: 41 U/L (Baseline)July 2025: 52 U/L (Elevated)July 14, 2026: 75 U/L (Markedly elevated; confirms progressive microvascular endothelial inflammation)Complement System:Elevated Complement C3 levels documented, indicating active innate immune system / complement pathway activation.Autoimmune & Serological Panels:Autoimmune screening panels (including standard ANA, rheumatoid/connective tissue serologies) have remained seronegative/flat, pointing toward a non-classical, innate autoinflammatory or microvascular endotheliitis process rather than structural autoimmune joint disease.2. Metabolic & Arterial Blood Gas Trends (Recurrent Episodes):Lactic Acidosis (Recurrent / Post-Exertional Spikes):Documented resting lactic acidosis post-exertion, peaking at 3.7 mmol/L (Normal: 0.5?1.8 mmol/L) measured 5 days post-cardiopulmonary exercise testing (CPET). Recurrent episodes of elevated lactate reflect persistent microvascular tissue hypoxia and anaerobic cellular stress following minor physical strain.Respiratory Alkalosis (Recurrent / Compensatory):Multiple arterial blood gas (ABG) panels demonstrating recurrent respiratory alkalosis. This reflects compensatory hyperventilation ("air hunger") driven by metabolic lactic acidosis and impaired pulmonary capillary gas exchange.Intravascular Hemoconcentration:Serum Albumin peaking at 5.0 g/dL during acute fluid shift episodes, indicating severe plasma volume loss out of the blood vessels and into peripheral tissue spaces (third-spacing).3. Pulmonary & Diagnostic Imaging:Pulmonary Function Tests (PFTs): Demonstrated an isolated reduction in pulmonary diffusion capacity ($DLCO$), indicating a diffusion barrier across the alveolar-capillary membrane.Chest CT Scans (Jan 2025, May 2026, July 27, 2026): Consistently demonstrate stable 3?4 mm noncalcified pulmonary nodules (bilateral) and stable biapical/pleural-based scarring/fibrotic changes. Stable 1 cm posterior pleural-based thickening noted.Pelvic/Gynecological Ultrasound: Confirmed functional ovarian cysts (follicular/corpus luteum type); currently managed with Slynd (drospirenone) for ovulation suppression and hormonal/fluid stabilization.